E. Ohman J or Asset Management AB Trims Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

E. Ohman J or Asset Management AB trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,859 shares of the medical equipment provider's stock after selling 1,213 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Intuitive Surgical were worth $14,293,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sycomore Asset Management raised its holdings in shares of Intuitive Surgical by 27.4% in the fourth quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider's stock worth $9,214,000 after buying an additional 4,079 shares during the period. Castleark Management LLC raised its holdings in shares of Intuitive Surgical by 3.4% in the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock worth $47,221,000 after buying an additional 2,990 shares during the period. Truist Financial Corp raised its holdings in shares of Intuitive Surgical by 3.0% in the fourth quarter. Truist Financial Corp now owns 248,092 shares of the medical equipment provider's stock worth $129,494,000 after buying an additional 7,298 shares during the period. Global X Japan Co. Ltd. raised its holdings in shares of Intuitive Surgical by 9.8% in the fourth quarter. Global X Japan Co. Ltd. now owns 46,289 shares of the medical equipment provider's stock worth $24,161,000 after buying an additional 4,140 shares during the period. Finally, Northeast Investment Management raised its holdings in shares of Intuitive Surgical by 3.1% in the fourth quarter. Northeast Investment Management now owns 89,170 shares of the medical equipment provider's stock worth $46,543,000 after buying an additional 2,685 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ISRG. Citigroup reissued a "buy" rating and issued a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Robert W. Baird dropped their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on Intuitive Surgical and gave the stock a "buy" rating in a research note on Monday, April 14th. Barclays dropped their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Finally, Royal Bank of Canada dropped their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus price target of $596.05.

Intuitive Surgical Stock Down 0.2%

Shares of Intuitive Surgical stock traded down $0.98 during trading on Friday, reaching $557.08. The company's stock had a trading volume of 1,103,774 shares, compared to its average volume of 1,641,815. The company has a market cap of $199.67 billion, a price-to-earnings ratio of 86.91, a P/E/G ratio of 5.85 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $413.52 and a 1-year high of $616.00. The company has a 50-day simple moving average of $521.99 and a two-hundred day simple moving average of $539.26.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. During the same quarter last year, the firm earned $1.50 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In related news, EVP Brian Edward Miller sold 8,900 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the transaction, the executive vice president now owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Robert Desantis sold 11,545 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the transaction, the executive vice president now owns 5,224 shares of the company's stock, valued at $2,607,925.28. This trade represents a 68.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,443 shares of company stock valued at $12,692,195 in the last quarter. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.